Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Deffered Revenue (2019 - 2025)

Silence Therapeutics' Non-Current Deffered Revenue history spans 7 years, with the latest figure at $55.5 million for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue rose 7.07% to $55.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $55.5 million, a 7.07% increase, with the full-year FY2025 number at $55.5 million, up 7.07% from a year prior.
  • Non-Current Deffered Revenue hit $55.5 million in Q4 2025 for Silence Therapeutics, roughly flat from $55.3 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for SLN hit a ceiling of $97.7 million in Q4 2021 and a floor of -$90.0 million in Q1 2022.
  • Historically, Non-Current Deffered Revenue has averaged -$25.9 million across 5 years, with a median of -$73.1 million in 2023.
  • Biggest five-year swings in Non-Current Deffered Revenue: crashed 198.19% in 2023 and later skyrocketed 176.67% in 2025.
  • Tracing SLN's Non-Current Deffered Revenue over 5 years: stood at $97.7 million in 2021, then dropped by 23.81% to $74.5 million in 2022, then plummeted by 198.19% to -$73.1 million in 2023, then surged by 170.83% to $51.8 million in 2024, then rose by 7.07% to $55.5 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for SLN at $55.5 million in Q4 2025, $55.3 million in Q3 2025, and $56.3 million in Q2 2025.